Reccurence of Kaposi's sarcoma after increased exposure to sirolimus

International Immunopharmacology

Volumn 6, Issue 13-14, 2006, Pages 2018-2022

  Boratyńska, Maria ^a   Zmonarski, Sławomir C ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Kaposi's sarcoma; Kidney transplantation; Malignancy; Mycophenolate mofetil; Sirolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FUNCTION; KIDNEY GRAFT; LUNG INFILTRATE; LUNG NODULE; MALE; MEDIASTINUM LYMPH NODE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RENAL GRAFT DYSFUNCTION; SKIN BIOPSY; SKIN DEFECT; SKIN TUMOR; TUMOR RECURRENCE;

DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASM RECURRENCE, LOCAL; SARCOMA, KAPOSI; SIROLIMUS;

EID: 33845198302     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.09.018     Document Type: Article

References (28)

1. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 64 (1997) 669-673
2. Serraino D., Angelett C., Carrieri M.P., Longo B., Piche M., Piselli P., et al. Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation 80 (2005) 1699-1704
3. Bais C., Van Geelen A., Eroles P., Mutlu A., Chiozzini C., Dias S., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cells 3 (2003) 131-143
4. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
5. Campistol J., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760-762
6. Zmonarski S., Boratynska M., Rabczynski J., Kazimierczak K., and Klinger M. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37 (2005) 964-967
7. Andrassy J., Graeb C., Rentsch M., Jauch K.W., and Guba M. mTOR inhibition and its effect on cancer in transplantation. Transplantation 80 (2005) 171-174
8. Guba M., von Bretenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
9. Gu J.J., Gathy K., Santiago L., Chen E., Huang M., Graves L.M., et al. Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion. Blood 101 (2003) 4958-4965
10. Messina E., Gazzaniga P., Micheli V., Guaglianone M.R., Barbato S., Morrone S., et al. Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer 108 (2004) 812-817
11. Engl T., Makarevic J., Relja B., Natsheh I., Muller I., Beecken W.D., et al. Mycophenolate mofetil modulates adhesion receptors of the beta 1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 5 (2005) 4
12. Leckel K., Beecken W.D., Jonas D., Oppermann F., Coman M.C., Beck K.F., et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumor cells. Clin Exp Immunol 134 (2003) 238-245
13. Vella J.P., Mosher R., and Sayegh M.H. Kaposi's sarcoma after renal transplantation. New Engl J Med 336 (1997) 176
14. Duman S., Toz H., Asci G., Alper S., Ozkahya M., Unal I., et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 17 (2002) 892-896
15. Montagnino G., Bencini P.L., Tarantino A., Caputo R., and Ponticelli C. Clinical features and course of Kaposi's sarcoma in kidney transplant patients: report 13 cases. Am J Nephrol 14 (1994) 121-126
16. Mota A., Arias M., Taskinen E.I., Paavonen T., Brault Y., Legendre C., et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4 (2004) 953-961
17. Durando B., and Reichel J. The relative effect of different systemic immunosuppressives on skin cancer development in organ transplant patients. Dermatol Ther 18 (2005) 1-11
18. Kauffman H.M., Cherikh W.S., Cheng J., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target of rapamycin inhibitors is associated with reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
19. Campistol J.M., Eris J., Oberbauer R., Friend P., Hutchison B., Morales J.M., et al. Sirolimus therapy after early withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
20. Kahan B.D., Yakupoglu Y.K., Schoenberg L., Knight R.J., Katz S.M., Lai D., et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80 (2005) 749-758
21. Boratynska M., and Rybka K. Malignant melanoma in patients with polyomavirus-BK-associated nephropathy. Transpl Infect Dis 7 (2005) 150-153
22. Koehl G.E., Andrassy J., Guba M., Richter S., Kroemer A., Scherer M.N., et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1319-1326
23. Guba M., Koehl G.E., Neppl E., Doenecke A., Steinbauer M., Schlitt H.J., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18 (2005) 89-94
24. Hussein M.M., Mooij J.M., and Roujouleh H.M. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead. Nephrol Dial Transplant 15 (2000) 1103-1104
25. Schrama Y.C., De Haas E.R.M., and Hene R.J. Concealed by veils. Nephrol Dial Transplant 15 (2000) 259-261
26. Gomez E., Aguado S., Rodriguez M., and Alvarez-Grande J. Kaposi's sarcoma after renal transplantation disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment. Nephrol Dial Transplant 13 (1998) 3279-3280
27. Eberhard O.K., Kliem V., and Brunkhorst R. Five cases of Kaposi's sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation 67 (1999) 180-184
28. Robson R., Cecka J.M., Opelz G., Budde M., and Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5 (2005) 2954-2960